Sanofi SAN -0.13% agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company ...

That’s equivalent to a premium of 33% over the closing price on May 30. Sanofi shares were down 1.2% as of 0750 GMT, at 86.53 euros a share.

Sanofi also said that it would increase the number of Phase 3 studies it is conducting by 50% between 2023 and 2025.

Sanofi says it's back to the drawing board on mRNA flu vaccines By Ludwig Burger June 28, 202310:35 PM PDTUpdated June 28, 2023 ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how ...

Sanofi, Formation Bio and OpenAI have jointly designed an AI-powered tool that will be rolled out in the former's phase 3 multiple sclerosis trials.

Sanofi last week closed its purchase of an early-stage immunology drug candidate from Dren Bio for up to $1.9 billion and in May agreed to acquire Vigil Neuroscience for about $470 million, adding ...